News from Tokyo Headquarters

Notice Concerning the Completion Timing for the Acquisition of Hitachi’s Diagnostic Imaging-related Business

Fujifilm Kyowa Kirin Biologics and Mylan EPD Announce Launch of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan

Transfer of Shares in Japan Tissue Engineering Co., Ltd. to TEIJIN LIMITED

Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce 76 million USD in Funding for Manufacturing and Innovation Center

Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility

FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody for Low- and Middle-Income Countries

Fujifilm to Expand its Viral Vector CDMO Services to Europe

Fujifilm wins Good Design Award with 27 products in a wide range of business fields

Centus Biotherapeutics Receives European Marketing Authorization for Equidacent^®, Biosimilar Avastin^®

Fujifilm launches droplet-shielding Mouthpiece “B1” and Endoscope Cover “P1”

FUJIFILM Diosynth Biotechnologies expands its partnership with Novavax to manufacture COVID-19 Vaccine Candidate at its Billingham site

FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate 

Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio^® (adalimumab-fkjp)

Fujifilm Kyowa Kirin Biologics Announces Approval of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan

Fujifilm to invest 100 billion yen (928 million USD) to expand its large scale biologics production facility in Denmark

Fujifilm’s New AI-based Technology for Lung Nodule Detection Now Approved for Use in Japan

FUJIFILM Diosynth Biotechnologies teams with COVID-19 Therapeutics Accelerator to reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies (FUJIFILM Diosynth Biotechnologies)

Fujifilm Invests $83M USD to Expand FUJIFILM Diosynth Biotechnologies Microbial Capacity